Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Assess the Safety of ARGX-213 in Healthy Volunteers
Sponsor: argenx
Summary
This study aims to assess the safety of ARGX-213 in healthy adults. Another aim is to measure the amount of ARGX-213 in the blood over time to learn how it moves through the body and acts in the body. The participants will remain in the study for approximately up to 21 weeks.
Official title: A Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-213 in Healthy Adult Participants
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2025-04-11
Completion Date
2026-06-30
Last Updated
2025-11-21
Healthy Volunteers
Yes
Conditions
Interventions
ARGX-213
Intravenous or subcutaneous administrations of ARGX-213
Placebo
Intravenous or subcutaneous administrations of placebo
Locations (1)
Altasciences
Montreal, Canada